Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
LYT-200 is a fully human IgG4 monoclonal antibody (mAb) targeting galectin-9, a potent oncogenic driver in leukemia cells and an immunosuppressive protein. It is being advanced in hematological malignancies such as acute myeloid leukemia AML, MDS, and solid tumors.
Lead Product(s): LYT-200
Therapeutic Area: Oncology Product Name: LYT-200
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: LYT-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Lead Product(s): VE202,Vancomycin Hydrochloride
Therapeutic Area: Gastroenterology Product Name: VE202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vedanta Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karuna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The funding will advance Phase 2 trial of company's therapeutic candidate, LYT-300, an oral prodrug of allopregnanolone, for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).
Lead Product(s): Allopregnanolone Prodrug
Therapeutic Area: Neurology Product Name: LYT-300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $11.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 01, 2023
Details:
LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: LYT-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LYT-300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
LYT-300 is a clinical therapeutic candidate that is in development as a potenƟal treatment for a range of neurological and neuropsychological condions. Developed using PureTech's Glyph™ technology plaƞorm, LYT-300 is an oral prodrug of natural allopregnanolone.
Lead Product(s): Allopregnanolone
Therapeutic Area: Psychiatry/Psychology Product Name: LYT-300
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
LYT-100 (deupirfenidone) was well-tolerated compared to pirfenidone in a healthy older adult crossover trial, informing dose selection for recently initiated trial in IPF.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022